07:00 , Aug 8, 2011 |  BC Week In Review  |  Clinical News

ALX-0081: Interim Phase II data

Interim data from 5 patients in the ongoing, single-blind, international Phase II TITAN trial showed that ALX-0081 followed by ALX-0681 inhibited vWF-mediated clotting as measured by a reduction in ristocetin cofactor compared to placebo. The...
08:00 , Jan 4, 2010 |  BC Week In Review  |  Clinical News

Anti-vWF Nanobody: Extension study data

Data from 22 patients with stable angina undergoing percutaneous coronary intervention (PCI) in the open-label extension of a Phase Ib trial showed that IV ALX-0081 significantly inhibited vWF-mediated clotting as measured by complete inhibition of...
07:00 , Aug 24, 2009 |  BC Week In Review  |  Clinical News

ALX-0681: Phase I data

Data from 36 healthy volunteers in a double-blind, placebo-controlled, single and multiple dose Phase I trial showed that daily injections of 10 mg ALX-0681 achieved complete inhibition of ristocetin cofactor for >14 days. There were...